(Q37289866)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

A systematic review on the effect of bevacizumab in exudative age-related macular degeneration (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1 reference

Johannes S.a.g. Schouten

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Ellen C La Heij

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Carroll A B Webers

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Igor J Lundqvist

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Fred Hendrikse

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

9 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

Graefe's Archive for Clinical and Experimental Ophthalmology

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

247

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843500%20AND%20SRC:MED&resulttype=core&format=json

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

15 January 2020

cites work

1 reference

12 December 2020

Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study.

1 reference

12 December 2020

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review

1 reference

12 December 2020

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study

1 reference

12 December 2020

Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration

1 reference

12 December 2020

Increased expression of angiogenic growth factors in age-related maculopathy

1 reference

12 December 2020

Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization

1 reference

12 December 2020

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

1 reference

12 December 2020

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

12 December 2020

Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.

1 reference

12 December 2020

Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration

1 reference

12 December 2020

[Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration]

1 reference

12 December 2020

Pharmacokinetics of intravitreal ranibizumab (Lucentis).

1 reference

12 December 2020

Bevacizumab in the treatment of colorectal cancer

1 reference

12 December 2020

[Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration]

1 reference

12 December 2020

Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration

1 reference

12 December 2020

The burden of age-related macular degeneration: a value-based analysis

1 reference

12 December 2020

Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases

1 reference

12 December 2020

Pegaptanib for neovascular age-related macular degeneration

1 reference

12 December 2020

Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration

1 reference

12 December 2020

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

1 reference

12 December 2020

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

1 reference

12 December 2020

Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments.

1 reference

12 December 2020

Ranibizumab for neovascular age-related macular degeneration

1 reference

12 December 2020

The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus

1 reference

12 December 2020

Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.

1 reference

12 December 2020

Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study

1 reference

12 December 2020

Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration

1 reference

12 December 2020

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage

1 reference

12 December 2020

Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts

1 reference

12 December 2020

Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration

1 reference

12 December 2020

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

1 reference

12 December 2020

Pharmacokinetics of intravitreal bevacizumab (Avastin)

1 reference

12 December 2020

Retinal pigment epithelium tears following ranibizumab for exudative age-related macular degeneration

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration

1 reference

12 December 2020

[Intravitreal bevacizumab for neovascular age-related macular degeneration]

1 reference

12 December 2020

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

1 reference

12 December 2020

Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

1 reference

12 December 2020

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study

1 reference

12 December 2020